Dual specificity protein kinase CLK2 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Dual specificity protein kinase CLK2 shows late clinical disease relevance led by osteoarthritis, knee. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P49760. Start with osteoarthritis, knee, then reuse UniProt P49760 as the stable protein anchor across project notes and exports.
Start with osteoarthritis, knee, then reuse UniProt P49760 as the stable protein anchor across project notes and exports.
Dual specificity protein kinase CLK2 shows late clinical disease relevance led by osteoarthritis, knee. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with osteoarthritis, knee because it currently carries late clinical support. Linked drugs include LORECIVIVINT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyDual specificity protein kinase CLK2
Review this target as Dual specificity protein kinase CLK2, mapped to UniProt P49760. Sequence length is 499 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Dual specificity protein kinase CLK2 as ChEMBL target CHEMBL4225, mapped to UniProt P49760. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Dual specificity protein kinase CLK2 is the right protein anchor across sources, using UniProt P49760 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why osteoarthritis, knee is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Dual specificity protein kinase CLK2 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P49760 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Dual specificity protein kinase CLK2 |
| UniProt Accession | P49760 |
| Component Type | Protein |
| Sequence Length | 499 aa |
Dual specificity protein kinase CLK2
Review this target as Dual specificity protein kinase CLK2, mapped to UniProt P49760. Sequence length is 499 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Dual specificity protein kinase CLK2 shows late clinical disease relevance led by osteoarthritis, knee. 2 more disease programs remain visible in the same review block.
Start review with osteoarthritis, knee because it currently carries late clinical support. Linked drugs include LORECIVIVINT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4797564 | 10.02 | IC50 | 0.096 | Preclinical |
| CHEMBL4797564 | 10.02 | Kd | 0.096 | Preclinical |
| CHEMBL4546504 | 9.58 | IC50 | 0.261 | Preclinical |
| CHEMBL3544966 | 9.4 | Kd | 0.4 | Preclinical |
| CHEMBL379218 | 9.29 | Kd | 0.51 | Preclinical |
| CHEMBL1230165 | 9.26 | IC50 | 0.55 | Clinical |
| CHEMBL5091238 | 9.22 | IC50 | 0.6 | Preclinical |
| CHEMBL4531334 | 9.12 | IC50 | 0.76 | Preclinical |
| CHEMBL1980407 | 9.1 | Ki | 0.7943 | Preclinical |
| CHEMBL4800084 | 9.09 | IC50 | 0.822 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 330 | 1,145 | 7.7 |
| assay format | 71 | 41 | 6.8 |
| cell-based format | 31 | 52 | 6.5 |
| subcellular format | 7 | 11 | 6.6 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 3 | 453 | 6.1 |
| cell-based format | 3 | 1 | 5.9 |